Surgeon in Ophthalmology, Massachusetts Eye and Ear Infirmary,

Assistant Clinical Professor, Harvard Medical School

Medical Director Associate Eye Physicians and Surgeons, Inc

Curiculum Vitae

Curriculum Vitae

 

Name:

Gary Edward   Borodic, MD

Office Address:

5 Cambridge   Center, Cambridge, MA 02142

1261 Furnace   Brook Parkway, Suite 15, Quincy, MA 02169

Work Phone:

617-770-0011

Work FAX:

617-770-0030

Place of Birth:

Providence, Rhode Island

 

Education

Year

Degree

(Honors)

Fields of Study
  (Thesis advisor for doctoral research degrees)

Institution

 

1970-1974

BA

with highest distinction

Chemistry/Bio-Chemistry

University of Rhode Island

1974-1978

MD

Medicine

University of Vermont

 

 

Postdoctoral Training

Year(s)

Title

Specialty/Discipline

(Lab PI for   postdoctoral research)

Institution

 

1978-1979

Intern

Internal Medicine

Rhode Island Hospital and

Brown University

1979-1980

Junior Assistant Resident

Ophthalmology

Rhode Island Hospital and

Brown University

1980-1981

Assistant Resident

Neurology

Yale New Haven Hospital

1980-1981

Post Doctorate Fellow

Neuroscience

Yale University

1981-1983

Resident

Ophthalmology

Massachusetts Eye and Ear Infirmary, Harvard Medical School

1983-1984

Chief Resident

Ophthalmology

Massachusetts Eye and Ear Infirmary, Harvard Medical School

 

Faculty Academic Appointments

Year(s)

Academic   Title

Department

Academic   Institution

1984-1988

Clinical Assistant

Ophthalmology

Harvard Medical School

1988-1993

Clinical Instructor

Ophthalmology

Harvard Medical School

1988-1990

Assistant Clinical Professor

Ophthalmology

Boston University

1993-present

Assistant Clinical Professor

Ophthalmology

Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

Year(s)

Position   Title

Department   (Division, if applicable)

Institution

 

1984-1987

Clinical Assistant

Ophthalmology

Massachusetts Eye and Ear Infirmary

1987-1994

Assistant Surgeon

Ophthalmology

Massachusetts Eye and Ear Infirmary

1994-2000

Associate Surgeon

Ophthalmology

Massachusetts Eye and Ear Infirmary

2000-Present

Surgeon

Ophthalmology

Massachusetts Eye and Ear Infirmary

Other Professional Positions

Year(s)

Position   Title

Institution

 

1987

Visiting Professor of Ophthalmology,   Neurology

University of Vermont

1988

Program Director

Benign Essential Blepharospasm Research   Foundation

1989

Visiting Professor

Dartmouth Medical    College

1992-1995

Industrial Safety Monitor

Food and Drug Administration Filings

1995

Round Table on Facial Movement Disorders

National Institute of Health

1999

Beaumont Lecturer in History of Medicine Series

University of Vermont College   of Medicine

1999-2006

University of Vermont Medical    College

Advisory Committee to Medical School   Dean

2002

Chair Pain Division

International Scientific and Therapeutic   Symposium on Neurotoxins

2004-2010    

 

Consultant for Botulinum toxin         Development for pure neurotoxin                  

Johnson and Johnson, Mentor Corporation

Major Administrative Leadership Positions

Local

Year(s)

Position   Title

Institution   (note if specific department)

 

1983-1984

Assistant Director of Residency Training   and Clinical Fellow

Harvard Medical    School

1984-1987

General Eye Service

Massachusetts Eye and Ear Infirmary

1984-1991

Attending, Oculoplastics and Orbital   Clinical Surgical

Massachusetts Eye and Ear Infirmary

1984-Present

Attending, Oculoplastic Trauma Service   Surgical

Massachusetts Eye and Ear Infirmary

1986-1987

Conference Lecturer and Organizer,   Oculoplastic Surgery

Harvard Medical    School

1986-1987

Greater Boston Residents Course and Lecturer,   Orbital Anatomy Course

Harvard Medical    School

1988

Director, Clinical Applications of   Botulinum Toxin

Harvard Medical    School

1989-1998

Oculoplastic Consultant, Facial Nerve Clinic

Massachusetts Eye and Ear Infirmary

 

1993-2003

 

Organizer and Attending Ophthalmologist Benign   Essential Blepharospasm Research Foundation, Facial Nerve Clinic

Massachusetts Eye and Ear Infirmary

2006, 2009-2010

Teaching conferences in Oculoplastic Surgery   for Ophthalmology Residents

Massachusetts Eye and Ear Infirmary

 

Regional

Year(s)

Position   Title

Institution   (note if specific department)

 

1986-1995

Attending Surgeon, Oculoplastics Clinic

Boston University    Hospital

1987-1995

Director, Oculoplastics Service

Boston University   School of Medicine, University Hospital

 

National and International

1988  

Director

Benign Essential Blepharospasm Research Foundation Meeting National

1993-1999              

Associate Medical Director

National Spasmodic Torticollis                                   Association

1999

Regional Meeting Director

Benign Essential Blepharospasm Research

2004

Regional Meeting Director

Benign Essential Blepharospasm Research   Foundation Meeting

2008

Regional Meeting Director

Benign Essential Blepharospasm Research   Foundation

Year(s)

Position   Title

Institution   (note if specific department)

 

 

Committee Service

Local

Year(s)   of

Membership

Name of Committee

Institution/Organization

Dates of Role(s)

Title of Role(s)

 

1985-1988

By Laws Committee

Massachusetts Eye and Ear Infirmary

1998-2001

Ad hoc committee on Wydase Use and   intra-ocular surgical complication rate

Massachusetts Eye and Ear Infirmary

2002-2008

Pharmacy Committee

Massachusetts Eye and Ear Infirmary

 

Regional            

Year(s)   of

Membership

Name of Committee

Institution/Organization

Dates of Role(s)

Title of Role(s)

 

1999-2006

Dean’s Advisory Committee                          

University of Vermont Medical    College

 

National

Year(s)   of

Membership

Name of Committee

Institution/Organization

Dates of Role(s)

Title of Role(s)

 

2004-2007

Initial Chair of Committee to   establish clinical study plan and sites for newer

botulinum toxin preparation

Sponsored by Mentor, Inc and now Johnson   and Johnson

 

Professional Societies

Year(s)   of

Membership

Society Name

 

Dates of Role(s)

Title of Role(s)

 

1973-Present

Phi Kappa Phi, Phi Beta Kappa

Member

1974-1994

American Medical Association

Member

1977-Present

Alpha Omega Alpha

Member

1983-1998

American Academy of Ophthalmology

Fellow

1984-1996

Massachusetts Medical Society

Member

1984-1993

Association for Research in Vision and Ophthalmology

Member

1987-1989

American Board of Ophthalmology

Test question preparation

1988

Benign Essential Blepharospasm Research   Foundation, Cambridge

National Program Chairman, Harvard Course   on applications of botulinum toxin for facial movement disease

1992-Present

American Society of Ophthalmic Plastic and   Reconstructive Surgeons

Fellow

1994-1998

National Spasmodic Torticollis

Associate Medical Advisor, Scientific   Committee

2001-2002

International Symposiums on Botulinum Toxin

Hanover Germany

 

Year(s)   of

Membership

Name of Committee

Institution/Organization

 

Dates of Role(s)

Title of Role(s)

 

Editorial Activities

 

Journals for which you serve as a reviewer

 

Ophthalmology

Neurology

Movement Disorders

Archives of Dermatology

Drug Safety

Ophthalmic Plastics and Reconstructive Surgery

The Medical Letter on Drugs & Therapeutics

Expert Opinion on Investigational Drugs

Expert Opinion on Pharmacotherapy

Journal of Pain

Ophthalmic Surgery, Lasers and Imaging

American Journal of Ophthalmology

Survey of Ophthalmology

Plastic and Reconstructive Surgery

Year(s)

Role

Journal Name

 

Honors and Prizes

Year

Name of Honor/Prize

Awarding   Organization

Achievement   for which awarded

(if unclear   from award title)

                                                                                                                                                                                                                                                                       

1974

Highest Distinction

University of Rhode Island

Chemistry and Humanities

1974

Phi Kappa Phi

University of Rhode Island

 

1977

Alpha Omega Alpha

University of Vermont

 

1999

Beaumont Annual Lecturer

University of Vermont Medical    College

Beaumont Honorary Lecturer

2010

Achievement Award

American Academy   of Ophthalmology, Chicago,    Illinois

Distinguished Service in   Teaching

 

Report of Funded and Unfunded Projects

Funding Information

Past

Year(s)

Grant title

 

Grant type and number

 

Role on Project (if PI or site PI, total indirect costs)

 

Description of the major goals

 

Many   projects were funded by limited grants from industry and private sources.

 

Year(s) funded

Role on Project/ Title of Project

 

One sentence description of the purpose of the   project

 

 

 

Report of Local Teaching and Training

Teaching of Students   in Courses          ^Year(s)

Course Title

Location

 

Type of student/audience

Level of Effort

 

1984-1988

Harvard   Medical Students Course in Ophthalmology

Harvard Medical    School

1998

Medical   Student Preceptor Teaching

Harvard Medical    School

2008

Medical   Student Preceptor Teaching

Harvard Medical    School

 

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)    

1989

Borodic GE.   Surgical Anatomy of the Eyelids, Annual Course on Oculoplastic Surgery

Harvard Medical    School

1990

Borodic GE.   Surgical Anatomy of the Nasolacrimal System, Orbital Course

Massachusetts Eye and Ear Infirmary

March 1990

Borodic GE.   The Concept of Using Botulinum Toxin to Achieve Facial Dynamic   Symmetry in Unilateral Facial Nerve Paralysis (Initiating the Human Studies Protocol:   Botulinum A Toxin to Achieve Facial Dynamic Symmetry at Massachusetts Eye and Ear Infirmary

Facial Nerve Meeting, Massachusetts Eye and Ear Infirmary

 

August 1991

Borodic GE.   Botulinum Toxin for the Treatment of Oscillopsia. Report of three cases.

Grand Rounds, Massachusetts Eye and Ear Infirmary

January 1992

Borodic GE, Ferrante R. Denervation field and Complications   Associated with Large Dose Botulinum Toxin Injections

Grand Rounds, Massachusetts Eye and Ear Infirmary

1995-2002

Borodic GE.   ENT Residency Course, BOTOX Applications

Annual Lecturer

Massachusetts Eye and Ear Infirmary

1999

Borodic GE.   Current Concepts in Botulinum Toxin Therapy

Grand Rounds, Massachusetts Eye and Ear Infirmary

Year(s)

Title

Location

 

Type of student/audience

Level of Effort

 

Clinical Supervisory and Training Responsibilities

Year(s)

Type of responsibility

Level of Effort

                                                                                                                                                                                                                      

1983-1986

Massachusetts Eye and Ear Infirmary

General Eye Service

 

1983-1988

Massachusetts Eye and Ear Infirmary Trauma Service

 

1987-1988

Massachusetts Eye and Ear Infirmary

Co-Acting Director Plastics Service

 

1988-1995

Director of Boston    University Oculoplastic   Clinic

 

1993-2002

Ophthalmology Consultant to   facial nerve Clinic

 

 

Formally Supervised Trainees:

Year(s)

Name and degrees/ Current   position

 

Describe the type of   supervision and the specific accomplishments of your trainee that occurred as   a direct result of your supervision (maximum one sentence)

 

1995

Vicki Kevadar, MD (Fellow)             Ophthalmic Plastic and   Reconstructive Surgery

 

Formal Teaching of Peers (e.g., CME and other continuing education courses)            

May 1990

Borodic GE. Overview and Surgical Variations of the   Hughs Flap, Massachusetts   Eye and Ear Infirmary Alumni Meeting

Single Presentation

Boston

May 1990

Borodic GE.   Mini Atlas of Eyelid Tumors

Massachusetts Eye and Ear Infirmary Alumni Meeting

Single Presentation

Boston

1991

Borodic GE.   Use of Gold Weight Implants for the Management of Paralytic   Lagophthalmos

Massachusetts Eye and Ear Infirmary Alumni Meeting

Single Presentation

Boston

January

1994

Borodic GE.   Otolaryngology and Botulinum Toxin, ENT

Grand Rounds, Massachusetts   Eye and Ear Infirmary

Single Presentation

Boston

April 2000

Borodic GE,   Acquadro MA. Botulinum Toxin, Efficacy   for Pain Application and Mechanisms, Pain Conference, Massachusetts General Hospital

Single Presentation

Boston

2000

Borodic GE.   Application of Botulinum Toxin for Migraine Headache, Discovery and   Development Status, Grand Rounds Ophthalmology, Massachusetts Eye and Ear Infirmary

Single Presentation

Boston

2002

Acquadro MA, Borodic GE. Botulinum Toxin for Human Pain, Head and Neck   Experience and Mechanisms, Pain Conference, Massachusetts General Hospital

Single Presentation

Boston

2006

Botulinum Toxin Pharmacology and Plastic   Application, Massachusetts   Eye and Ear Infirmary Oculoplastic

Lecture   (2 hours)

January 2010

Borodic GE.   Diagnosis and Management of Eyelid Lesions, with Emphasis on Lid   Reconstruction, Massachusetts   Eye and Ear Infirmary Residents Program

Single Presentation

Boston

January 2011

Borodic GE.   Diagnosis and Management of Eyelid Lesions, with Emphasis on Lid   Reconstruction

Massachusetts Eye and Ear Infirmary Residents Program

Single Presentation

Boston

 

Year(s)

Title(s) or topic(s) or   talks

Number of talks in a single course

 

Course Name (Sponsor, if any)

Location(s) (city or country)

 

 

Local Invited Presentations

March 1985

Borodic GE, Townsend DJ. Ophthalmologic Evaluation of Meige Syndrome   and Clinical Applications of Botulinum Toxin

Boston Neurological Society

January 1987

Hochberg FH, Borodic GE, Growdon J,   Henneman.   Treatment of Focal Forearm   Dystonias with Oculinum, A Report of the First Thirteen Cases

Department of Neurology & Human Studies   Committee

Massachusetts     General Hospital, Neurology Grand Rounds

September 1989

Borodic GE.   Botulinum Toxin: Therapeutic Applications in Ophthalmic and Neurologic   Diseases

Grand Rounds – Neurosurgery

Massachusetts     General Hospital

Brigham and Women’s Hospital

August 1989

Borodic GE.   Ophthalmic and Neurologic Applications of Botulinum A Toxin

Neurologic/Neurosurgical Grand Rounds

Brigham and Women’s Hospital

March 1990

Borodic GE.   Application of Botulinum Toxin for Larger Muscle Dystonias/ Grand   Rounds

Braintree Hospital

New     England Sinai Hospital

October 1990

Borodic GE.   Topographic Diffusion of Botulinum Toxin and Regional   Complications/Clinical Applications of Botulinum Toxin/ Neurology Grand   Rounds

Spaulding Rehabilitation    Hospital

October 1990

Borodic GE.   Reconstruction of the Upper and Lower Eyelid/ Combined Grand Rounds,   Ophthalmology

Boston University/Tufts University

1991

Borodic GE.   Review of Reconstructive Techniques for Upper and Lower Eyelids

Greater Boston Review Course on Oculoplastic and   Reconstructive Surgery

January 1995

Borodic GE.   Botulinum Toxin for the Treatment of Human Muscle Disease

Ether Dome-Oral Surgery Grand Rounds, Massachusetts General Hospital

 

Report of Regional, National and International Invited Teaching and Presentations

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings and

List   abstracts published and exhibits presented at meetings during the last 3   years which have not already been published as full length manuscripts. May also list   all abstracts or exhibits, regardless of date or publication as full-length   manuscript, which received special recognition at a meeting (e.g., juried   poster presentation, meeting commendation).

Invited Presentations and Courses

Regional

Year(s)

Title of presentation or   name of course/ Type of presentation/role(s) (note if presentation the result   of a selected abstract)

Location (Sponsor, if any)

 

June 1980

Borodic GE, Geltzer A, Kinder, R. Scatter Retinal Photocoagulation and   Hyperglycemic State

New England Ophthalmology Society

1983

Borodic GE, Chess J, Bienfang DC. Temporal Arteritis and the Vertebral Artery   Syndrome

New England Ophthalmology Society

1984

Borodic GE, Sadun A, Bienfang DC. The Optic Nerve and Sarcoidosis

New England Ophthalmology Society

October

1984

Borodic GE.   Clinical Use of Botulinum Toxin Neurology/ Grand Rounds

New     England Deaconess Hospital

1984

Borodic GE, Townsend DJ, Papale J. The Optic Nerve and Leukemia

New England Ophthalmology Society

June 1985

Borodic GE, Townsend DJ. Treatment of Neurologic Blepharospasm with   Botulinum Toxin

New England Ophthalmology Society

Audio Digest Ophthalmology (vol. 23, no.   17, September 1985)

May 1987

Borodic GE, Beyer CK. Autogenous Dermis Fat Graft for the   Treatment of Synthetic Implant Extrusion in an Eviscerated Socket

New England Ophthalmology Society

1987-1991

Borodic GE.   Lecturer, Medical    College Courses

Boston University

1988

Borodic GE.   Lecturer, Medical    College Courses

University of Vermont

Dartmouth University    Medical College

January 1989

Borodic GE.   Use of Botulinum Toxin for Hemifacial Spasm/Neurosurgery Grand Rounds

Massachusetts     General Hospital

May 1989

Borodic GE.   Research and Clinical Applications of Botulinum A Toxin in   Ophthalmology and Medicine

Vermont Ophthalmology Society Meeting, Manchester, Vermont

May 1989

Borodic GE.   Reversible Blindness after Surgical Drainage of Orbital Abscess

New England Ophthalmological Society

August 1990

Borodic GE.   Applications of Botulinum A Toxin for the Treatment of Segmental   Dystonia

Neurology Grand Rounds

Dartmouth Medical    College

1991

Borodic GE.   Evaluation and Management of Involuntary Neurologic Blepharospasm

Greater Boston Review Course on Oculoplastic and Reconstructive   Surgery

October

1992

Borodic GE.   Diagnosis and Evaluation of Orbital Blowout Fractures/ Grand Rounds

Boston University/Tufts University

May 1992

Borodic GE.   Blepharospasm, An Update

New England Ophthalmology Society

 

May 1992

 

Borodic GE.   Current Concepts in Botulinum Toxin Therapy/New England Oculoplastic Course

Tufts University

1994

Borodic GE.   Lecturer, Medical    College Courses

Tufts University

Boston University

1994

Borodic GE.   In Vitro Demonstration of Phaco-Chop Maneuver

Tufts University Course on Phacoemulsification Surgery

June 1994

Borodic GE.   Live Surgery Demonstration of Levator Resection Techniques/   Oculoplastics Series

Tufts University

December 1994

Borodic GE.   Botulinum toxin and Strabismus

Boston University

May 1995

Borodic GE.   Surgical Anatomy of the Anterior Orbit/ Annual Course on Eyelid   Surgery

Tufts University

August 1998

Borodic GE.   Botulinum Toxin as an Anti-flammatory, Neurobiologic Effects

University of Vermont

1998

Borodic GE.   Lecturer, Medical    College Courses

University of Vermont

1998

Borodic GE, Acquadro MA. Symposia on Neurobiology of Botulinum   Toxin, Physiology

University of Vermont

1998

Borodic GE.   Surgical Methods for Creating Tarsorraphy

New England Ophthalmology Society

1998

Borodic GE.   Update on BOTOX

New England Ophthalmic Plastics Society

1998

Borodic GE.   Molecular Mechanisms of Botulinum Toxin

New England Oculoplastic Meeting

January 1999

Borodic GE.   Botulinum Toxin/ Grand Rounds

Tufts New England    Medical Center

1999

Borodic GE.   Beaumont   History of Medicine Lecturer, History of Botulinum Toxin Development for the   Treatment of Human Diseases

University of Vermont

March 1999

Borodic GE.   Botulinum Toxin in Ophthalmology

Invited Lecturer, Tufts University

March 1999

Borodic GE.   Use of Mitomycin C in Sebaceous Eyelid Cancer

New England Oculoplastic Meeting, Stowe, Vermont

May 1999

Borodic GE.   Outcome instrument for the Morbidity Measurements in Hemifacial   Spastic Disease

New England Ophthalmology Society

Spring 1999

Borodic GE.   Surgical Tarsorraphy, Review of Techniques and Applications

New England Ophthalmology Society

December 1999

Borodic GE.   Botulinum Toxin for Human Essential Headache Disorders

New England Otolaryngology Society

May 2000

Borodic GE.   Botulinum Toxin for Essential Headache Disorders

New England Otolaryngology Society

June 2000

Borodic GE.   Botulinum Toxin for Essential Headache Disorders

New England Ophthalmology Society

 

October 2000

Borodic GE.   Neurobiology of Botulinum Toxin

Special Conference with Department of Neurobiology,   Physiology

University of Vermont, College    of Medicine

May 2001

Borodic GE.   Botulinum Toxin for Chronic Facial Pain Disorders and Mechanism of   Action

New England Ophthalmology   Society

2007

Borodic GE. Update   on Botulinum Toxin Pharmacology

New England Ophthalmology Society, Boston, Massachusetts

September 2010

Borodic GE.   Pharmacology Update on Botulinum Toxin

Cape Cod Review Course in   Ophthalmology

September

2010

Borodic GE.   Management of Blepharospasm

Cape Cod Review Course in   Ophthalmology

October 2011

August

2012

Borodic GE.   Botulinum Toxin for Management of Headache

Cape Cod Review Course in   Ophthalmology

Borodic   GE. History of Botulinum Toxin as a Medical

Agent – Past, Present, and Future

Sixth Annual Dartmouth Botulinum Symposium and Workshop

National

Year(s)

Title of presentation or   name of course/ Type of presentation/role(s) (note if presentation the result   of a selected abstract)

Location (Sponsor, if any)

 

1983

Borodic GE, Beyer CK, Mullin J, Foster   S. Conjuntival Amyloidosis, an Unusual   Case of Ptosis

Oculoplastic Research Symposium, American Academy of Ophthalmology,   Chicago, Illinois

1984

Borodic GE, Sadun A, Bienfang DC. Pulsating Exophthalmos After a Closed Head   Injury

Frank Walsh Society

1984

Sadun A, Borodic GE. Optic Neuropathy Secondary to Ophthalmic   Artery Aneurysm

Frank Walsh Society

April 1984

Borodic GE, Bienfang D. Anterior Optic Nerve Circulation Changes   Observed in Temporal Arteritis

Neurology Clinical Conference, Roberto   Heros, Maryland

May 1985

Borodic GE, Conte J, Aswad M, Hilles S,   Robinson D, Melvin C, Caron LA, Foster CS.

Aqueous Humor Leukotriene Concentrations in   Animal Models of Inflammation Association for Research in Vision and   Ophthalmology

1986

Borodic GE, Townsend DJ. Dose Response Relationships of Oculinum in   the Treatment of Neurologic Blepharospasm

Association for Research in Vision and   Ophthalmology

1987

Borodic GE.   Lecturer, Medical    College Courses

University of Utah

1988

Borodic GE, Cozzolino DJ, Ferrante R. Histologic Changes in Human Orbicularis   Oculi Muscle Treated with Botulinum Toxin

American Academy   of Ophthalmology, Las Vegas,    Nevada

1988

Townsend DJ, Borodic GE. Toxin Injection Technique

Meige Disease Meeting, Cambridge, Massachusetts

1989

Borodic GE.   Lecturer, Medical    College Courses

Ohio State

August 1989

Borodic GE, Ferrante R, Cozzolino D. Geometric Field of Action of Botulinum   Toxin Using Acetylcholinesterase Stain

Blepharospasm Foundation, Ohio State    University

1989

Borodic GE, Young R, Cozzolino D, Weigner   A. Innervation Zone Analysis of   Orbicularis Oculi Muscle and its Significance to Botulinum A Toxin Therapy

American Academy   of Ophthalmology, New Orleans,    Louisiana

1990

Borodic GE.   Lecturer, Medical    College Courses

Duke University

1990

Borodic GE, Ferrante R. Effects of Repeated Injections of Botulinum   A Toxin on the Histology of Human Orbicularis Oculi Muscle

American Academy   of Ophthalmology, Atlanta,    Georgia

1990

Borodic GE, Mill L, Joseph M. Blepharospasm, Spasmodic Torticollis. Clinical Application of Botulinum A Toxin   for Adult Onset Spasmodic Torticollis

American Academy   of Ophthalmology, Atlanta,    Georgia

September 1990

Borodic GE, Fay L, Joseph M, Ferrante R,   Mills L, Cozzolino D. Regional Toxin   Spread, Botulinum Toxin Diffusion Kinetics and Complications in the   Applications of Botulinum A Toxin

Essential Blepharospasm, Meige Disease,   Facial Dystonia Foundation, Duke    University

Durham, North Carolina

1990

Borodic GE, Fay L, Joseph M, Ferrante R,   Mills L, Cozzolino D.   Sub-classification of Adult Onset Spasmodic Torticollis and   Standardization in the Botulinum Toxin Injection Strategy

Essential Blepharospasm, Meige Disease,   Facial Dystonia Foundation, Duke    University

Durham, North Carolina

September 1990

Borodic GE.   Botulinum A Toxin in Clinical Medicine: Dysphagia, Ophthalmic   Complications and Regional Toxin Spread

U.S. Food and Drug Administration

1991

Medicinal Applications of Botulinum A Toxin

US Army Chemical Meeting, Boston, Massachusetts

Spring 1991

Borodic GE, Jankovic J. Clinical Applications of Botulinum A Toxin   in Neuro Medicine and Ophthalmology

American Academy of Neurology

Spring 1991

Borodic GE.   Demonstrated Method of Injection of Botulinum Toxin into Cervical   Muscles for the Treatment of Spasmodic Torticollis

American Academy of Neurology

June 1991

Borodic GE.   Botulinum Toxin for Treatment of Facial Dyskinesias, Scientific Review   of Techniques

American Academy   of Ophthalmology, Regional Meeting, Cambridge,    Massachusetts

1991-1992

Borodic GE.   Botulinum Toxin and Adult Onset Spasmodic Torticollis

New England Meeting of the National Spasmodic   Torticollis Association

1992

Borodic GE.   Lecturer, Medical    College Courses

Baylor University

August 1992

Borodic GE, Sillman J, Waters K. Digitalization and Computer Analysis of   Human Facial Movements

Baylor Medical    College

August 1992

Borodic GE, Pearce B, Ferrante R. New Concepts in Botulinum Toxin Pharmacology

Baylor Medical    College

1993

Borodic GE.   Lecturer, Medical    College Courses

University of Wisconsin

November 1993

Borodic GE, Pearce LB, Ferrante R. Anti-botulinum Toxin Antibodies After   Repetitive Injection of Botulinum Toxin for the Treatment of Essential   Blepharospasm

American Association of Ophthalmic Plastic   and Reconstructive Surgeons

24th Annual Scientific   Symposium, Chicago, Illinois

November 1993

Borodic GE, Pearce LB. Regional Denervation, Implication for   Standardization of Botulinum Activity Important for Medicinal Use

Inter-agency Meeting on Botulinum Toxin

University of Wisconsin,   Madison, Wisconsin

1994

Borodic GE.   Lecturer, Medical    College Courses

University of Minnesota

Columbia University

1994

+Borodic   GE.   Differential Dysphagia Rates for Spasmodic   Torticollis Based on Botulinum Toxin Formulation.

University of Minnesota

November 1994

Borodic   GE. Current Approaches to the Use of   Botulinum Toxin for Spasmodic Torticollis

Annual   Scientific Symposium, National Spasmodic Torticollis Association,

Orlando, Florida

December 1994

Borodic   GE. Dynamic Lines in the Periorbital   Region, and Botulinum Toxin Applications in Ophthalmology

Columbia University Course on   Facial Plastic and Reconstructive Surgery

1995

Borodic GE.   Lecturer, Medical    College Courses

National   Institutes of Health-Neuroscience Division

Round   Table on Movement Disorders

February 1995

+Borodic   GE, Johnson E, Goodnough M.   Standardization and Formulation Issues in the Preparation of Botulinum   Therapeutic Toxin

National   Institute of Health

December 1995

+   Borodic GE, Goode M. Immunoresistance   in Craniocervical Dystonia Patients Treated with Repetitive Botulinum Toxin   Injections.

Interagency   Botulism Meeting, Center of Disease Control, Atlanta, Georgia

1996

+   Borodic GE, Quigg C. Photophobia and   Essential Blepharospasm

American   Society of Ophthalmic Plastic and Reconstructive Surgeons

1996

+   Borodic GE. Pharmacology of Botulinum Toxin

Interagency   Botulism Meeting, US   Army, Fort Dietrick

1998

Borodic   GE.     Botulinum Toxin Can Precipitate   Myasthenia Crisis

American   Society of Ophthalmic Plastic and Reconstructive Surgeons

October 1999

Borodic   GE.   Outcome Instrument for the   Morbidity Measurements in Hemifacial Spastic Disease- Validation Methods

American   Society of Plastic and Reconstructive Surgeons

October 1999

Borodic   GE. Mitomycin C as Adjuvent   Chemotherapy for Post Operative Treatment of Sebaceous Cell Carcinoma

American   Society of Plastic and Reconstructive Surgeons

September   2001

+Borodic   GE.   Outcome Measurements and Efficacy   Criterion

FDA   Advisory Panel Meeting Bethesda,    Maryland

2004

Borodic   GE Botulinum Toxin for Hypersecretion Blepharitis

American   Society of Ophthalmic plastic and Reconstructive Surgery, New Orleans

2004

Borodic   GE Antibodies to botulinum toxin after   repeated use in cosmetic applications

American   Society of Ophthalmic plastic and Reconstructive Surgery, New Orleans

October 2004

Borodic   GE.   Botulinum Toxin Course

American Academy of Ophthalmology, New Orleans, Louisiana

October 2005

Borodic   GE.     Botulinum Toxin Course

American Academy of Ophthalmology, Chicago, Illinois

2005

Borodic   GE.     Botulinum Toxin Course

American   Society of Ophthalmic Plastic Reconstructive Surgery, Chicago, Illinois

2005

Kahn   J, Bushwach K, Leese P, Borodic GE, Johnson E, Goodnough M, Milizio C,   Weilert D.   A First Look at the “Next   Generation” High Purity Neurotoxins   Safety and Efficacy Results in the First Patients

American   Society of Ophthalmic Plastic Reconstructive Surgery , Chicago, Illinois  

2005

Bushwach   K, Kahn J, Leese P, Borodic GE, Johnson E, Goodnough M, Milizio C, Weilert D.   High Purity Neurotoxins Safety and Efficacy   Results in the First Patients

American   Society of Plastic Reconstructive Surgery, San Diego, California

2006

Borodic   GE. Botulinum Toxin Course Contributor

American Academy of Ophthalmology, Las Vegas, Nevada

November 2007

Borodic   GE.     Botulinum Toxin Course

American Academy of Ophthalmology, New Orleans, Louisiana

November 2008

Borodic   GE.     Botulinum Toxin Course

American Academy of Ophthalmology, Atlanta, Georgia

October 2009

Borodic   GE.   Botulinum Toxin Course

American Academy of Ophthalmology, San Francisco, California

2009

Borodic   GE, Hinkle D, Cai Y.   Drug induced   Graves Disease from CTLA-4 Suppression

American   Society of Ophthalmic Plastic and Reconstructive Surgery, San Francisco, California

2009

Borodic   GE. Orbicularis Oculi Myo-Osseous Fixation: A New   Treatment for Benign Essential Blepharospasm and Blepharospasm Associated   with Diffuse Facial Dystonia (Meige Syndrome)

American   Society of Ophthalmic Plastic and Reconstructive Surgery, San Francisco, California

2009

Borodic   GE.   Enhancement of Gold Weight   Ballasting Effect with Placation of Lateral Retinalculum- Lateral Canthal   Tendon via Single Self Drilling Titanium Screw

American   Society of Ophthalmic Plastic and Reconstructive Surgery, San Francisco, California

October 2010

Borodic GE.   Botulinum Toxin Course (co-director)

American   Academy of Ophthalmology Chicago, Illinois

2010

Borodic GE.  Video Presentation of Cases of Blepharospasm   and Meige Syndrome

Treated with Myo-osseous Fixation- Browpin,   One to Two Year Follow-up

American Society of Ophthalmic Plastic and   Reconstructive Surgery, Chicago,    Illinois

2010

Borodic   GE. Comparative Compositional   Pharmacology of Botulinum Toxin Preparations

American Society of Ophthalmic   Plastic and Reconstructive Surgery, Chicago,    Illinois

2011

Borodic GE. Canalicular Stenosis Treated with Self   Expanding 3-0 Supramyd Loop

American Society of Ophthalmic Plastic and   Reconstructive Surgery, Orlando,    Florida

2011

Borodic GE. Orbicularis Oculi Myo-Osseous Fixation   (MOF-Facepin, BrowPin) for Blepharospasm not Responsive to Botulinum Toxin, 3   Year Experience

American   Society of Ophthalmic Plastic and Reconstructive Surgery, Orlando, Florida

2011

Borodic   GE. Use of Brow Pin (FacePin) for the Treatment of Involutional and   Paralytic Brow Ptosis and Midface Descent

American   Society of Ophthalmic Plastic and Reconstructive Surgery, Orlando, Florida

2011

Borodic   GE. Use of Hyaluronidate Filler for the   Treatment of Lower Facial Deformity Associated with Hemifacial Spasm

                       American Society of Ophthalmic Plastic and Reconstructive Surgery, Orlando, Florida

2012                Borodic GE. Cosmetic Botulinum Toxin and Facial Fillers: An Introductory Course

                        American Academy of Ophthalmology Chicago, Illinois

International

Year(s)

Title of presentation or   name of course/ Type of presentation/role(s) (note if presentation the result   of a selected abstract)

Location (Sponsor, if any)

 

June 1982

Borodic   GE, Gragoudas E, Brockhurst R.   Choroidal Neovascularization Complicating Congenital Optic Nerve Pits

International   Neuro-Ophthalmology Symposium, Hamilton, Bermuda

1984

+   Borodic GE, Bienfang DC.  The Topographic Neuropathology of   Opsoclonus

International   Congress of Neuro-Ophthalmology, Antwerp,    Belgium

1985

Borodic GE.   Lecturer at Neuro-Ophthalmic   Society

International Neuro-Ophthalmic Symposium

September 1987

+Borodic GE. Evidence of Drug Resistance with Repeated   Injections of Oculinum in Essential Blepharospasm

5th International Meeting of the   Benign Essential Blepharospasm Research Foundation

1988

+   Borodic GE, Townsend DJ, Cozzolino DJ.   Dose Relationships of Botulinum   Toxin for Blepharospasm

6th   International Conference on Facial Dyskinesia, Cambridge, Massachusetts

 

1988

 

+   Borodic GE, Weigner A, Young R. Innervation Zone Analysis and Botulinum   Toxin Therapy (Blepharospasm)

6th   International Conference on Facial Dyskinesia, Cambridge, Massachusetts

May 1992

+   Borodic GE, Ferrante R, Pearce B. Review of Histologic Changes in Muscle After   Clinical Botulinum Toxin Injections and Importance of Diffusion

International   Symposium on Botulinum Toxin, Madison,    Wisconsin

November 1999

+Borodic   GE, Acquadro MA.     Retrospective   Analysis of 97 Botulinum Toxin Patients with Blepharospasm, and Essential   Headache Disorders

International   Botulinum Toxin Conference, Orlando,    Florida

November 1999

+Tarsy   D, Borodic GE.   Botulinum Toxin   Injection in Patients with Myasthenia Gravis

International   Botulinum Toxin Conference, Orlando,    Florida

2002

+Borodic   GE, Acquadro MA.   Botulinum Toxin for   Chronic Facial Pain 140 Patient Experience

International   Botulinum Conference, Hanover, Germany

2005

+Borodic   GE, Goolsy H, Ferrante R.   Histologic   Analysis of Pure Botulinum Type A Neurotoxin on Motor Denervation After Point   Injection

International   Botulinum Toxin Conference, Denver,    Colorado

2008

+Pellet   S, Tepp W, Borodic GE, Johnson EA.     Neuronal Cell Based Assay for Detection of Botulinum Toxin Antibodies

International   Botulinum Toxin Conference, Lake Majori, Dino,    Italy

 

 

Report of Clinical Activities and Innovations

Current Licensure and Certification

Year

Type of License or Certification

 

1979

Diplomat, National Board of   Examiners

1979-Present

Rhode Island Board of Registration

1981-Present

Massachusetts Board of Registration

1985

Board Certification:   Ophthalmology

 

Practice Activities (Current)

List all clinical activities, both those at Harvard and its affiliates and those outside Harvard, and for each indicate:

Year(s)

Type of activity

Name and location of practice

Level of activity

 

1985-present

Ophthalmology

Associated Eye Physicians &   Surgeons, Inc., Quincy

Three days week

1985-present

Outpatient surgeries

Massachusetts   Eye and Ear Infirmary, Boston

One to four days per month

2005-present

Ophthalmology/Oculoplastics

Associated Eye Physicians &   Surgeons, Inc., Cambridge

Two days week

 

If you have no current clinical activities, but have practiced in the past you may provide a brief (1-2 sentence) description of those prior activities

Clinical Scientific Accomplishments and Innovations:

  1. 1.Botulinum Toxin Pharmacology:
    1. a.Principle investigator for phase 2 and phase 3 trials on botulinum toxin for facial spastic diseases. (Oculinum-TM, now Botox)
    2. b.Discovered and Published the first use of botulinum toxin pharmaceuticals for the treatment of a primary pain syndrome (tension and myofascial headache, post operative pain 1991-1995)(see Press release on Oct 13, 2010 on FDA approval for Chronic migraine).
    3. c.Recognized the increasing problem of immunity after continuous use of botulinum toxin, and the corresponding compositional defect in BOTOX responsible for this complication. With publication and use of patents, the problem received industrial attention to this issue resulting in formulation changes of existing neurotoxin (BOTOX and DYSPORT). The future directional activities towards purer botulinum based products ensued with industry investing new compositions and formulation relative to drug safety.
    4. d.Initial discovery finding extra-ocular muscle necrosis using lidocaine anesthetic formulations in the absence of hyaluronidase for peri-bulbar injections
    5. e.Introduced and popularized the notion of photophobia as an important component to Meige Disease-Blepharospasm
    6. f.Conceived and designed a novel surgical procedure for the treatment of benign essential blepharospasm using neurophysiologic and oculoplastic principles, conducting initial clinical study, publishing and teaching the procedure to other surgeons.
    7. g.Described a novel neuronal cell based assay to assess botulinum toxin immunologic resistance.
    8. h.Designed multiple clinical studies to assess efficacy of botulinum toxin in disfiguring and blinding facial spastic disease, dystonia and facial esthetics.
    9. i.Teaching surgical technique to residents and fellows when

Name of clinical innovation

Describe the influence or potential influence of the   innovation on clinical care or practice management, including how the   innovation is used or has been implemented locally (at HMS), regionally,   nationally or internationally; if developed as a member of a committee,   describe your contribution (1-2 sentences)

 

Report of Technological and Other Scientific Innovations

Innovation (date if applicable)

Patent, if any, pending or awarded /If described in   print/on web, provide citation

 

Describe the influence or potential influence of the   innovation on research or clinical care, including how the material is used   locally (at HMS), regionally, nationally or internationally; if developed as   a member of a committee, describe your contribution (1-2 sentences)

 

 

US Patents

Borodic   GE   US Pat 5,053,005   filed Apr 1989, issued Oct 1991

Chemomodulation   of Curvature of the Juvenile Spine

Orthopedic   surgeons have initiated pilot trials on this indication

Borodic GE   US Pat 5,183,462   filed Aug 1990, issued Feb 1993

Controlled Administration of Chemodenervating Pharmaceuticals

(this patent brought   interest in using botulinum toxin for the treatment of many spastic diseases

and quantitating diffusion   dynamic)

Borodic   GE   US Pat 5,298,019   filed Jan 1993, issued Mar 1994

Controlled Administration of Chemodenervating Pharmaceuticals

(interested industry in   treatment of spasticity and facial pain, bruxism)

Borodic   GE   US Pat 5,401,243   filed Apr 1993, issued Mar 1995

Controlled Administration of Chemodenervating   Pharmaceuticals

(interested industry in   regional denervation assays to test batch to batch consistency, this method   is practiced by at least one major company)    

Johnson   E, Goodnough M, Borodic GE   US Pat   5,696,077 filed Oct 1994, issued Dec   1997

Pharmaceutical Composition   Containing Botulinum B Toxin Complex

(formulation improvements   interested industry to improve formulation of materials to limit the amount   of toxoid in vials and helped tremendously in limiting immunity after   multiple injections)

Adopt as industry standard

Borodic   GE   US Pat 7,537,773   filed Aug 1998, issued May 2009

Chemodenervating Pharmaceutical as Anti-Inflammatory Agent

(interested industry in the use of the neurotoxin   for the treatment of pain syndromes and human inflammation)

Borodic,   GE   US Pat 6,429,189   filed Dec 1999, issued Aug 2002

Cytotoxin (non-neurotoxin) for the Treatment of Human Headache   Disorders and Inflammatory Diseases

(a possible mechanism for   eliminating the neuroparalytic effect and retain non paralytic pharmacologic   properties of the neurotoxin, useful for disease treatment )

Borodic   GE   US Pat 7,459,164   filed May 2002, issued Dec 2008

Composition for Therapeutic and Cosmetic Botulinum Toxin

(attention to eliminating   pooled human blood products in the botulinum toxin formulations by use of   recombinant protein excipients)

Borodic   GE   US Pat 7,491,403   filed Dec 2002, issued Feb 2009

Pharmaceutical Botulinum   Toxin Compositions

( this patent family draws   attention to the effect of excipients on toxin diffusion and biologic unit   potency, this patent deals with chemical methods for allowing a safer   administration of neurotoxin and increasing potency of units while limiting   complications caused by diffusion)

Borodic   GE   US Pat 7,335,367   filed March 2003, issued Feb 2008

Treatment of Chronic Chalazion and Hordeolum with Botulinum   Toxin

(botulinum by working a   cholinergic input to meibomian glands can prophylactic ally treat patient   with chronic recurrent chalazia)

Borodic   GE   US Pat 7,670,608   filed March 2003, issued March 2010

Selection of Patients with Increased Responsiveness to Botulinum   Toxin

(method for selecting   migraine and tension headache patients more likely to respond to neurotoxin)

Borodic   GE US Pat 7,270,826     filed Jan 2004, issued Sep 2007

Methods of Using Botulinum   Toxin for the Treatment of Hypervolemic Lip Deformity (lip ectropion)

(another cosmetic   application of botulinum toxin)

Borodic   GE   US Pat 7,691,394   filed April 2005, issued April 2010

High-Potency Botulinum Toxin Formulations

(a novel method of altering   potency which will be tested among various formulations in future studies by   Johnson and Johnson)

 

Foreign   Patents

Borodic   GE   Japan Pat 3510886   filed Jun 1993, issued Jun 2004

Pharmaceutical Composition Containing Botulinum B Complex

Borodic   GE   Canada Pat 2,138,020   filed Jun 1993, issued Feb 1999

Pharmaceutical Composition Containing Botulinum B Complex

Borodic   GE   Japan Pat 4381477   filed Jan 1994 from US filed Jan 1993, issued Oct 2009

Method for Treating Myofascial Pain

(first medical disclosure   on use of botulinum toxin for the primary treatment of human pain)

Borodic   GE   Canada Pat 2,510,058   filed Dec 2003, issued Mar 16, 2010

Improved Pharmaceutical Botulinum Toxin Compositions

Borodic   GE     China Pat 100525831C   filed Dec 2003, issued Aug 2009

Improved Pharmaceutical Botulinum Toxin Compositions

Borodic   GE   Colombia   filed Dec 2003, issued Dec. 2009

Improved Pharmaceutical Botulinum Toxin Compositions

Borodic   GE   European Patent Convention Pat   1594523   filed Dec 2003, issued Mar   2009

Improved pharmaceutical botulinum toxin compositions

Borodic   GE   India Pat 206509   filed Dec 2003, issued Apr 2007

Improved Pharmaceutical Botulinum Toxin Compositions

Borodic   GE   Indonesia Pat IDP0024294   filed 2003, issued Sep 2009

Improved Pharmaceutical Botulinum Toxin Compositions

Borodic   GE   Mexico Pat 268879   filed Dec 2003, issued Jul 2009

Improved Pharmaceutical Botulinum Toxin Compositions

 

 

 

Borodic   GE   New Zealand Pat 540425   filed Dec 2003, issued Jul 2009

Improved Pharmaceutical Botulinum Toxin Compositions

Borodic   GE   Singapore Pat 112594   filed Dec 2003, issued Jul 2007

Improved Pharmaceutical Botulinum Toxin Compositions

Borodic   GE   South Africa Pat 2005/04982   filed Dec 2003, issued May 2007

Improved Pharmaceutical Botulinum Toxin Compositions

Borodic   GE   Australia Pat 2004216901   filed Mar 2004, issued Feb 2010

Treatment of Chronic Chalazion and Hordeolum with Botulinum   Toxin Injections

Borodic   GE   Mexico Pat 276893   filed Mar 2004, issued Jun 2010

Treatment of Chronic Chalazion and Hordeolum with   Botulinum Toxin Injections

Borodic   GE, Acquadro MA   Australia Pat   2004216904   filed Mar 2004, issued   Apr 2010

Treatment of Sinusitis Related Chronic Pain and Headache   with Botulinum Toxin Injections

(unique pain application   for botulinum toxin)

Borodic   GE, Acquadro MA   China Pat   20048000591   filed Mar 2004, issued   Jun 2010

Treatment of Sinusitis Related Chronic Pain and Headache   with Botulinum Toxin Injections

Borodic   GE, Acquadro MA   New Zealand Pat   541779   filed Mar 2004, issued May   2008

Treatment of Sinusitis Related Chronic Pain and Headache   with Botulinum Toxin Injections

Borodic   GE, Acquadro MA   Singapore Pat   114943   filed Mar 2004, issued Sep   2007

Treatment of Sinusitis Related Chronic Pain and Headache   with Botulinum Toxin Injections

Borodic   GE, Acquadro MA   South Africa Pat   2005/06715   filed Mar 2004, issued   Mar 2004

Treatment of Sinusitis Related Chronic Pain and Headache   with Botulinum Toxin Injections

 

 

Borodic   GE   European Patent Convention Pat   1706141   filed Jan 2005, issued Dec   2009

Use of Botulinum for the Treatment of Hypervolemic Lip Deformity

Borodic   GE   France Pat 1706141   filed Jan 2005, issued Dec. 2009

Use of Botulinum for the Treatment of Hypervolemic Lip Deformity

Borodic   GE   Germany Pat 1706141   filed Jan 2005, issued Dec. 2009

Use of Botulinum for the Treatment of Hypervolemic Lip Deformity

Borodic   GE   Italy Pat 1706141   filed Jan 2005, issued Dec 2009

Use of Botulinum for the Treatment of Hypervolemic Lip Deformity

Borodic   GE   Spain Pat 1706141   filed Jan 2005, issued Dec 2009

Use of Botulinum for the Treatment of Hypervolemic Lip Deformity

 

US Applications

Borodic   GE, Acquadro MA   App.   2002/0192239   filed Jan 2002

Use   of Botulinum Toxin for the Treatment of Chronic Facial Pain

 

Borodic   GE   App. 2002/0187164   filed Aug 2002

Cytotoxin   (non-neurotoxin) for the Treatment of Human Headache Disorders and Inflammatory   Diseases

 

Borodic   GE   App. 2004/0037853   filed May 2003

Composition   for Therapeutic and Cosmetic Botulinum Toxin

 

Borodic   GE   App. 2004/0151741   filed Dec 2003

Pharmaceutical   Botulinum Toxin Compositions

 

Borodic   GE   App. 2004/0175390   filed Mar 2004

Selection   of Patients with Increased Responsiveness to Botulinum Toxin

 

Borodic   GE   App. 2004/0175400   filed Mar 2004

Treatment   of Chronic Chalazion and Hordeolum with Botulinum Toxin

 

Borodic   GE, Acquadro MA   App.   2004/0247606   filed Mar 2004

Treatment   of Sinusitis Related Chronic Facial Pain and Headache with Botulinum Toxin Injections

 

Borodic   GE   App. 2005/0208075   filed Jan 2005

Methods   of Using Botulinum Toxin for the Treatment of Hypervolemic Lip Deformity (lip   ectropion)

 

Borodic   GE, Acquadro MA   App.   2006/0147471   filed Feb 2005

 

Compositions,   Methods and Devices for Preparing Less Painful Botulinum Toxin Formulations

 

Borodic   GE   App. 2006/0182767   filed Apr 2005

High-Potency   Botulinum Toxin Formulations

 

 

Borodic   GE   App. 2007/0009555   filed Jan 2006

Botulinum   Toxin and the Treatment of Primary Disorders of Mood and Affect

 

Borodic   GE   App. 11/447,984   filed Jun 2006

Botulinum   Toxin and the Treatment of Depressive, Anxiety and Sleep Disorders

 

 

Borodic   GE   App. 12/083,058   filed Oct 2006

Botulinum   Toxin Based Pharmaceutical Composition

 

Borodic   GE   App. 2008/0118533   filed Jan 2008

Treatment   of Chronic Chalazion and Hordeolum with Botulinum Toxin

 

Borodic   GE   App. 2009/0148476   filed Dec 2008

Chemodernervating   Pharmaceutical as Anti-Inflammatory Agent

 

Borodic   GE   App. 2009/0324647   filed Aug 2009

Albumin-Free   Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase   and Methods of Use

 

Borodic   GE   App. 2002/0187164   filed Aug 2002

Cytotoxin   (non-neurotoxin) for the Treatment of Human Headache Disorders and   inflammatory Diseases

 

 

Foreign Applications

Borodic   GE   France App. 03814518.1   filed Dec 2003

Improved Pharmaceutical Botulinum Toxin Compositions

 

 

Borodic   GE   Germany App. 60326887.0

filed   Dec 2003

Improved   Pharmaceutical Botulinum Toxin Compositions

Borodic   GE  

Japan   App. 2004-564369 filed Dec 2003  

Improved   Pharmaceutical Botulinum Toxin Compositions

Borodic   GE   Netherlands App. 03814518.1   filed Dec 2003

Improved   Pharmaceutical Botulinum Toxin Compositions

Borodic   GE   United Kingdom App.   03814518.1   filed Dec 2003

Improved   Pharmaceutical Botulinum Toxin Compositions

 

 

Borodic   GE   Japan App. 2006-506300   filed Mar 2004

 

 

Treatment   of Chronic Chalazion and Hordeolum with Botulinum Toxin Injections

 

Borodic   GE   Japan App. 2006-506302   filed Mar 2004

Treatment   of Sinusitis Related Chronic Pain and Headache with Botulinum Toxin Injections

Borodic   GE   European Patent Convention App.   4718358.7   filed Mar 2004

Method   of Selecting Patients Suffering from Pain for Treatment with Botulinum Toxin

 

Borodic   GE   European Patent Convention App.   07020648.7   filed Oct 2007

Method   of Selecting Patients Suffering from Pain for Treatment with Botulinum Toxin

 

Borodic   GE   European Patent Convention App.   06772449.2   filed Jun 2006

Botulinum   Toxin and the Treatment of Depressive, Anxiety and Sleep Disorders

(patent   deals with trans-cranial effects of subcutaneous botulin toxin)

 

Report of Education of Patients and Service to the Community

Activities  

May include a brief, one-sentence description of each role if needed (optional)

Year(s)

Organization or institution   / Role (Sponsor, if any)

 

One sentence description   (optional)

 

1988, 1990, 1994, 1998, 2001, 2003, 2006, 2008

Patient Support Group Meeting for Dystonias   of the Face

 

Educational Material for Patients and the Lay Community

Group materials (in print or other media) into three   categories

 

 

Year

Title

Type of contribution (Sponsor, if any)

Citation, if any

 

1986

Dan Rather CBS Evening News   (8 min)

Interview

The Tragedy on the Loss of Botulinum   Toxin Because of Product Liability Insurance Issues

1987

MacNeil-Lehrer news Hour

Interview

Product Liability Insurance Problems   and the Treatment of Blepharospasm (20 min)

1999

Benign Essential   Blepharospasm Letters

Author

Managing Blepharospasm Over the Years

2008

Allure Magazine

Contributor,   worked with

author

Botulinum Toxin Possible Spread   and Effects on the Human Brain

Year

Title

Type of contribution (Sponsor, if any)

Citation, if any

 

 

 

Report of Scholarship

Include only manuscripts that are published or accepted   for publication (forthcoming) in print or other media; do not include   manuscripts that have been submitted but not accepted for publication or   those that are in preparation; Please use bold-faced type for your name in   the authorship list. Numbering of contributions should start with   "1" in each new section.

 

Peer reviewed publications in print or other media

Ashikkaga   T, Borodic GE, Sims EAH:

Multiple Daily Insulin Injections and   the Treatment of Diabetic Retinopathy

Diabetes 1978 vol. 27:592 (Abstract:   JAMA Oct. 6, 1978)

(Abstract: International Medicine   News, Oct. 1978)

Borodic   GE, Gletzer A, Kinder R:

Scatter Retinal Photocoagulation and   the Hyperglycemic State

(Abstract: Ophthalmology Times, Nov.   1980)

Calderone   JP, Chess J, Borodic GE, Albert DM:

            Intraocular   Pathology in Trisomy 18 (Edwards Syndrome)

            British Journal of Ophthalmology vol.   67, no. 3:162 1983

Borodic   GE, Sadun A, Bienfang DC:

           Pulsating Exophthalmos after a   Closed Head Injury

           Publication: Case Records of MGH,   New England Journal of Medicine,

           Vol. 311, no. 8:520-528, 1983

Borodic   GE, Gragoudas E, Brockhurst R:

Choroidal Neovascularization Complicating   Congenital Optic Nerve Pits

           Archives of Ophthalmology vol.   102:229-231, 1984

Borodic   GE, Beyer C, Millin J, Foster S:

            Immunoglobulin   Deposition in Primary Conjunctival Amyloidosis

American Journal of Ophthalmology vol.   98:617-622, 1984

Walsh   TJ: Book review by Borodic GE:

Neuro-Ophthalmology; Clinical Signs   and Symptoms

Lea & Febiger, 1985. Arch. of   Ophthal.

Char   DH: Book Review by Borodic GE:

           Thyroid Eye Disease. Williams   & Wilkins, 1985 Arch. of Ophthal.

Jankovic   J Book review by Borodic GE:

Facial Dyskinesias, Raven Press, 1988   Arch of Ophthalmol

 

Borodic   GE, Townsend DJ:

Oculinum (Botulinum Toxin) for the   Treatment of Facial Spastic Disease

Oculoplastic Orbital &   Reconstructive Surg. Hornblass, Williams, Wilkins, Baltimore 1988

 

Borodic   GE, Townsend DJ:

Dose-Response Relationships in 241 Patients   with Blepharospasm

Cambridge, Mass.   1988 Meige Disease Foundation Meeting

Ears, Nose & Throat Journal, 1988   vol. 67 (12):914

Borodic   GE, Weigner A, Young R:

Motor Point Analysis and Botulinum Toxin   Administration

Cambridge, Mass. 1988 Meige Disease Foundation Meeting  

Ears, Nose & Throat Journal, 1988 vol 67:915

Borodic   GE, Townsend DJ:

           Method of Injecting Botulinum   Toxin for the Treatment of Blepharospasm

           1988 Meige Disease Foundation   Meeting. Ears, Nose & Throat   Journal, 1988 vol 67:915

Borodic   GE, Cozzolino D:

Blepharospasm and its Treatment with Emphasis   on the Use of Botulinum A Toxin

Invited by Robert Goldwyn, Editor in   Chief, Plastic & Reconstructive Surgery  

vol. 83, no. 3:546-553, 1989

Borodic   GE, Townsend DJ, Beyer C:

Management of Implant Extrusion in an   Eviscerated Socket with Autogenous Dermis Fat Graft Ophthalmic Plastic &   Reconstructive Surgery vol. 5 (2):144-149, 1989

 

Borodic   GE, Miller D, Bienfang D:

Opsoclonus Report of Three Autopsies   and Literature Reviews

Neuro-ophthalmology Into the Nineties,   Smith JL, Katz RS,

           Dutton Press, Hialeah, FL,   1989

Borodic   GE, Joseph M, Fay L, Cozzolino D, Ferrante R:

Botulinum A Toxin for the Treatment of   Spasmodic Torticollis, Dysphagia and Regional Toxin Spread

Head & Neck, 12:392-398, 1990

Borodic   GE:

Involuntary Eyelid Closure and Orbicularis   Paralysis

Current Opinions in Ophthalmology Vol.   1:30, 1990

Borodic   GE, Mills L, Joseph M:

Botulinum A Toxin for Adult Onset Spasmodic   Torticollis

Ophthalmic Plastic and Reconstructive   Surgery 87:2, 285-289, 1991

Borodic   GE, Cozzolino D, Weigner A, Ferrante R, Young R:

Orbicularis Oculi Innervation Zone and   Implications for Botulinum A Toxin Therapy

Ophthalmic Plastics and Reconstructive   Surgery, Volume 7, No 1, 54-60, 1991

Borodic   GE, Pearce LB, Johnson E, Schantz E:

Clinical and Scientific Aspects of   Therapeutic Botulinum Toxin Administrations.   Ophthalmology Clinics of N America,   September, Vol. 4, No. 3, 1991 (Invited)

McKenna   MJ, Cheney M, Borodic GE:

Management of Facial Paralysis after Intracranial   Surgery

Contemporary Neurosurgery, 13(22),   1-8, 1991

Borodic   GE:

Botulinum A Toxin for (Expressionistic)   Ptosis Overcorrection after Frontalis Sling

Ophthalmic Plastic and Reconstructive   Surgery 8(2):137-42, 1992

Borodic   GE, Pearce LB, Smith K, Joseph M:

            Botulinum   Toxin for Spasmodic Torticollis, Multiple vs. Single Point Injections per Muscle

Head and Neck 14:33-37, 1992

Borodic   GE, Cheney M, McKenna M:

Contralateral Injection of Botulinum Toxin   to Achieve Facial Dynamic Symmetry for the Treatment of Hemifacial Spasm

            Ophthalmic   Plastic and Reconstructive Surgery, 90(6),972-7,1992

Borodic   GE, Ferrante R:

Histologic Effects of Repeated Botulinum   Toxin over Many Years in Human Orbicularis Oculi Muscle

Journal of Clinical Neuro-Ophthalmology   12(2):121-127, 1992

Borodic   GE, Pearce LB:

United States Pharmacopial Drug   Information for the Health Care Professional

January, 1992

Borodic   GE, Ferrante R, Wiegner AW, Young RR:

Treatment of Spasticity with Botulinum   Toxin

Ann Neurol 31(1):113,1992

Borodic   GE, Smith K, Pearce LB, Ferrante R:

Botulinum B Toxin as an Alternative to   Botulinum A Toxin, a Histologic Study

Ophthalmic Plastic and Reconstructive   Surgery, 9(3):182-90, 1993

Borodic   GE, Metson R, Townsend D, McKenna M, Pearce LB:

Botulinum Toxin for Aberrant Facial Nerve   Regeneration. Dose Response Relationships.

Ophthalmic Plastic and Reconstructive   Surgery, (91)6, 1042-5, 1993

Borodic   GE, Ferrante R, Pearce B:

Review of Histologic Changes in Muscle   after Clinical Botulinum Toxin Injections and Importance of Diffusion

           International Symposium on   Botulinum Toxin, Madison Wisconsin in Botulinum and tetanus

           Neurotoxins edited by BR   Dasgupta, Plenum Press, New York,    New York 1993                        

Borodic   GE:

Hemifacial Spasm, Evaluation and   Therapy

Textbook of Botulinum Toxin Therapy   Eds J Jankovic, M

           Hallet, Marcel Dekker, New York, Hong Kong,   Chapter 24, page 331-353,1994

Borodic   GE, Aldersen K, Pearce, Ferrante R:

Histology and Pharmacology of   Botulinum Toxin Injections

Textbook of Botulinum Toxin Therapy   Eds J Jankovic, M

           Hallet, Marcel Dekker, New York, Hong Kong,   Chapter 10, page 119-158, 1994

Borodic   GE, Pearce LB, Johnson E:

Botulinum Toxin Antibodies after Repetitive   Eyelid Injections

           Ophthalmology, 101:1158-9, 1994

First   E, Pearce LB, Borodic GE:

Dose Standardization with Botulinum Toxin   for Human Use

Lancet, 343(8904):1035, 1994

 

Pearce   LB, Borodic GE, First E, MacCallum R:

            Measurement   of Botulinum Toxin Activity: Evaluation of the Lethality Assay

Toxicology and Applied Pharmacology   128, 69-77, 1994

Borodic   GE, Ferrante R, Pearce LB, Smith K:

Histologic Assessment of Dose Related Diffusion   and Muscle Fiber Response after Therapeutic Botulinum Toxin Injections

            Movement   Disorders 9(1):31-9, 1994

Acquadro   MA, Borodic GE:

Treatment of Myofascial Pain with Botulinum   Toxin

Anesthesiology 80(3):705-706, 1994

Borodic   GE:

Cystic Lesions of the Orbit

Principles and Practice of   Ophthalmology (Harvard Method in Ophthalmology).(completed) W B Saunders 1994. (second edition 1998)(third   edition, in press)

Borodic   GE, Pearce LB, Johnson E:

Botulinum Toxin Antibodies after Repetitive   Eyelid Injections

           Ophthalmology, 101:1158-9, 1994

Borodic   GE:

Therapeutic Botulinum Toxin. Letter,   The Lancet, 344: 1370, 1994

Pearce   LB, Borodic GE, First E:

Botulinum Toxin Standardization

Journal of the Royal Society of   Medicine, 343:1035, 1994

Borodic   GE, Pearce LB:

           New Concepts in Botulinum Toxin Therapy.   Drug Safety 11(3)): 145-152, 1994

Borodic   GE, Pearce LB, Duane D, Johnson E:

Antibodies to Botulinum Toxin

Neurology 45(1):204, 1995

Pearce   LB, Borodic GE, Johnson EA, First ER, MacCallum R:

The Median Paralysis Unit: A More Pharmacologically   Relevant Unit of Biologic Activity for               Botulinum Toxin

           Toxicon   Vol 33, no 2 pp 217-227, 1995

            Toxicon   35:9, 1373, 1997 (Review)

Pearce   LB, First E, Borodic GE:

Botulinum Toxin Standardization: Death   vs. Localized Denervation

           J R Soc Med 88(4): 239-240, 1995

Borodic   GE:

Use of Botulinum Toxin in Facial Plastic   Surgery

           ed Cheney M Williams and Wilkins,   1996

Borodic   GE:

Evaluation and Management of Ptosis

           ed Cheney M Williams and Wilkins,   1996

 

Borodic   GE, Johnson, Goodnough M, Schantz E:

Botulinum Toxin, Immunologic Resistance,   and Problems with Available Materials

(by invitation), 46:26-29   Neurology,1996

 

Pardo   FS, Borodic GE:

Long Term Follow Up of Patients Undergoing   Definitive Radiation Therapy for Sebaceous

            Cell   Carcinoma of the Ocular Adnexae

International Journal Radiation   Oncology Biol Phys 1534 1189-90, 1996

 

Borodic   GE:

Eyelid Botulinum Toxin Injections Can Cause   Myasthenic Crisis

The Lancet, Dec 5;352(9143):1832, 1999

 

Troll   G, Borodic GE:

Diplopia After Cataract Surgery Using   4% Lidocaine in the Absence of Wydase ™

Clin Anesth. Nov; 11(7):615-6 1999

 

Hayashi   N, Borodic GE, Karesh JW, Tolentino MJ, Remulla HD,

Van Wesep RA, Grossniklaus HE,   Jakobiec FA, Green WR:

Giant Cell Angiofibroma of the Eyelid

Ophthalmology. 1999 Jun; 106(6):1223-9

 

Borodic   GE:

Botulinum Toxin Issues and Applications

           Current Opinions in   Otolaryngology, 1999 Dec 5;352(9143):1832

 

Tarsy   D, Bhattachayya N, Borodic GE:

Myasthenia Gravis after Botulinum A Toxin   for the Treatment of Meige Syndrome

Movement Disorder 15(4): 736-8,   2000    

 

Borodic   GE, Acquadro MA, Johnson E:

Botulinum Toxin for the Treatment of Pain   and Inflammation

           Expert Opinion on Investigational   Drugs 10(8): 1531-1544, 2001

 

Borodic   GE, Acquadro MA:

Botulinum Toxin for the Treatment of Chronic   Facial Pain

American Journal of Pain, vol 3, no 1   21-27, 2002

 

Borodic   GE and Acquadro MA:

Botulinum Toxin for the Treatment of Intractable   Facial Pain, Experience with 140 Cases

Acta Pharmacologica 2002     (supplement)

 

Acquadro   MA, Borodic GE:

Review of Botulinum Toxin for Pain   Management in the Head and Neck

Journal of Anesthesia, (by invitation)   in press 2004

 

   Borodic GE, Bartley M, Slattery W,   Glasscock M, Johnson E, Malazio C, Goodnough M, Acquadro MA, McKenna M:

Botulinum Toxin for Aberrant Facial Nerve   Regeneration: Double-Blind, Placebo-Controlled Trial Using Subjective Endpoints

Ophthalmic Plastic and Reconstructive   Surgery, 116(1):36-43 2005

 

   Acquadro MA, Borodic GE:

Botulinum Toxin Efficacy for the Treatment   of Pain

Journal of Clinical Anesthesia   17(5):328-30 2005

 

Johnson   E, Borodic GE:

Review of Current Therapeutic Indications   Using Botulinum Toxin

The Basic and Clinical Science of   Botulinum Therapy by Invitation,

scheduled publication 2005

 

   Borodic GE:

Immunologic Resistance after Repeated Botulinum   Toxin Type A Injections for Facial Rhytides

Ophthalmic Plastic Reconstructive Surgery,   22(3):239-40 2006

 

Johnson   EA, Borodic GE, Acquadro MA:

Medical Applications of Botulinum Neurotoxins,   Published in Comprehensive   Sourcebook of Bacterial Protein Toxins   (Third edition) edited by Alouf JE and Popoff MR, Chapter 58,

         pages 959-975, 2006  

 

   Borodic GE:

Botulinum Toxin, Immunologic Considerations   with Long-Term Repeated Use, with Emphasis on Cosmetic Applications

Facial Plastic Surgery Clinic North   Am 15(1):11-6, v., 2007

 

   Pellett S, Tepp WH, Clancy CM, Borodic GE,   Johnson, EA:

A Neuronal Cell-Based Botulinum Neurotoxin   Assay for Highly Sensitive and Specific Detection of Neutralizing Serum Antibodies

FEBS lett. 581(25):4803-8, 2007

 

Borodic   GE:  

Discussion Regarding Botulinum Toxin, Immunologic   Considerations and Long Term Repeated Use with Emphasis on Cosmetic Application.   Facial Plastic Surgery Clinic North   Am

Volume 17 No 4, 633-637, 2009

 

   Borodic GE:

Orbicularis Oculi Myo-Osseous Fixation:   A New Treatment for Benign Essential Blepharospasm and Blepharospasm Associated   with Diffuse Facial Dystonia (Meige Syndrome)

Ophthalmic Surgery, Lasers and Imaging   41(3):360-9 2010

 

   Borodic GE:

Functional Significance of Fat Surrounding   the Orbicularis Oculi Muscle

Ophthalmic Plastic and Reconstructive   Surgery 2010

 

Borodic   GE, Hinkle D, Cai Y:          

Drug induced Graves Disease from   CTLA-4 Suppression

Ophthalmic Plastic and Reconstructive   Surgery   2010

 

Borodic   GE:   

Use of Fillers as Adjunct Therapy for   the Treatment of Lower Face Hemifacial Spasm

Ophthalmic Plastic and Reconstructive   Surgery   2013

 

Borodic   GE, Hinkle D:          

Reply to Letter to Editor entitled:   “Re: “Drug-induced Graves Disease from CTLA-4 Receptor Suppression"

Ophthalmic Plastic and Reconstructive   Surgery   2013

 

Borodic   GE, Caruso P, Aquadro M, Chick, S:            

Parry Romberg Syndrome Vasculopathy   and its Treatment with Botulinum Toxin

Ophthalmic Plastic and Reconstructive   Surgery   2013

 

 

 

 

 

 

 

 

 

 

 
         
       

BOOKS:

   
         
   

For each item indicate:

   

-Type of material (e.g., syllabus, teaching case)

   

-If published in print or on the web, provide citation

   

-Intended audience (including course number if     applicable) and brief description of how the material is used locally (at     HMS), regionally, nationally or internationally; if developed as a member     of a committee, describe your contribution (1-2 sentences)

   

 

                             
   

Borodic GE,     Townsend DJ

   

Illustrated     Methods of Eyelid Surgery (A Surgical Atlas)

   

           WB Saunders, 1994. (English and     Spanish translations)Chapter 1-5 and Chapter 8

   
   

Borodic GE

   

Surgical Anatomy of the Eyelids (Chapter 1)

   
   

Borodic GE

   

Canthoplasty (Chapters 2)

   

Borodic GE

Management of Graves and   Thyroid Eye Disease (Chapter 3)

 

Borodic GE

Surgical Reconstruction of the Human Eyelids (Chapter 4)

 

Borodic GE  

Ptosis Surgery   (Chapter 5)

 

Borodic GE  

Medical and Surgical Management of Blepharospasm (Chapter   8)

 

 
 

Group materials into the following categories:

-Proceedings of meetings or other non-peer reviewed   research publications

-Reviews, chapters, monographs and editorials

-Books/Textbooks for the medical or scientific community

-Case reports

-Letters to the Editor

 
 

Clinical Guidelines   and ReportsFor each item indicate:

-Type of material (e.g., clinical protocol or standard   of care)

-If published in print or on the web, provide citation

-Description of the how the material is used locally (at   HMS), regionally, nationally or internationally; if developed as a member of   a committee, describe your contribution (1-2 sentences)

 
 

ThesisProvide   full citation for doctoral thesis

 
       

Narrative Report

 

In general,   we suggest the following structure for the narrative:

  • An opening paragraph that provides an overall   summary of your major activities and achievements. Include an estimate of the proportion of   your effort dedicated to teaching, research, clinical service, administrative   activities and other relevant professional roles
  • Description of achievements in your Area of   Excellence (Investigation, Teaching and Educational Leadership, or   Clinical Expertise and Innovation); may include a description of work in   progress such as pending grants or manuscripts in preparation
  • Description of contributions to Teaching and   Education (if not your area of excellence). This may include a description of   mentorship activities not discussed elsewhere in the CV
  • Description of contributions in Significant   Supporting Activities, if any
  • A final paragraph that integrates and   summarizes the contributions described above

 

My career in ophthalmology has been a hybrid, encompassing   interests in basic ophthalmic surgical practice, oculoplastic surgery,   pharmacology of botulinum toxin relative to ophthalmology as well as other   specialties. Particular focus continues to be benign essential blepharospasm   and related disorders. Although an orphan disease, this condition can be   blinding and therefore devastating to quality of life. My interest in this   disease did not only originate from ophthalmology and eye plastic surgical   experience, but also prior training received in the field of neurology. For   this condition, my work has contributed to acceptance of botulinum toxin for   this indication (1980’s), refinement in the administration techniques,   enhanced understanding of treatment method and materials (1990’s), and more   recently new clinical approaches.

In the period between 1990-1995, published work of led to   understanding defects in BOTOX formulation that threatened the efficacy of   this agent for potentially millions of patients. Toxoid in the vials was an   issue leading to secondary resistance in numerous high dose applications, a   fact missed by US FDA evaluators and denied by industry at that time. By use   of academic literature and national conference, this problem eventually   received appropriate attention. In 1998, the two major pharmaceutical   companies changed their formulations. Over   the last several years, I conceived, based on surgical anatomy and   neurophysiology, a novel minimally invasive surgical procedure for refractory   treatment of blepharospasm and related disorders. This procedure has now been   presented at two national academy meetings and has started to be reproduced   internationally by other surgeons. Two   papers have been published with further publications in the planning.

In research and development, I have interested industry to   commit tremendous resources in the study and development of botulinum   pharmaceuticals while still maintaining an active practice in eye plastics   and ophthalmology. Most recently, I have assisted Johnson and Johnson’s   Mentor Corporation to initiate a novel botulinum formulation for national   studies using altered type A botulinum toxin with a novel formulation of   excipients. This program has been expanded to treatment in over 3000 patients   nationally and will hopefully provide the market with another supplier of   materials to reduce cost based on competition and perhaps even provide a more   contained pharmacologically active agent allowing for safer high dose   administration. I have received over 40 US and foreign patents to facilitate   this degree of investment.

In clinical research area,   I co-published the first article on the treatment of human headache   disorders, an observation that was further corroborated in the mid 1990’s and   just recently (Oct-2010), expanded to an FDA approval of human chronic   migraine headache disorders for migraine prophylaxis. Migraine and associated   headache disorders are the second most common reason a human being will use a   medication.   I will continue to try to   work in the scientific medical and civic issues relative to these   discoveries.

Civic activities that can be cited relate to helping the   original botulinum toxin effort obtain product liability insurance after the   national study had been halted for one year between 1985-1986. This activity   required interviews with Dan Rather and an appearance on the McNeil-Leher   News Hour. I have participated in advocacy for the Benign Essential   Blepharospasm Foundation, National Spasmodic Torticollis Foundation, and   National Trigeminal Neuralgia Foundation.      

I have always enjoyed teaching at Massachusetts Eye and   Eye Infirmary and occasionally in other Boston Hospitals and continue to   welcome interested residents or medical students in my office or operating   room. In the past, I have authored a book primarily written to assist   ophthalmology residents and fellows on plastic techniques on the eyelid. In   the past, I have functioned as acting co-director of the Massachusetts Eye   and Ear Infirmary plastic service, director of Boston University’s   plastic service, Co-ophthalmic director of Massachusetts Eye and Ear   Infirmary Facial Nerve Clinic, temporary director of eye trauma service, and   attending on the general eye service. Recently (October 2010), I received the   achievement award from the American    Academy of   Ophthalmology for sustained efforts to this organization’s teaching programs   over the years. However, I still believe that the best opportunity for   medical student, resident and fellow teaching is on hospital and clinic based   training. When asked, I am happy to try to contribute in an appropriate   fashion.      

Gary E. Borodic. MD

P: 617.770.0011
F: 617.770.0030 

Quincy Office

1261 Furnace Brook Pkwy
Suite 15
Quincy, MA 02169

Waltham Office

1440 Main St. 
Suite 201

Waltham, MA 02451